Olema, Novartis and metastatic breast cancer
Olema Pharmaceuticals (OLMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sam ...
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant ...
Olema Pharmaceuticals prepares for its OPERA-02 study, targeting ER+/HER2- breast cancer. Read why OLMA stock could benefit ...
Olema Pharmaceuticals, Inc. (“Olema” or “”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast ...
Zacks.com on MSN1d
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 BillionNovartis NVS has entered into a global license and collaboration agreement with PTC Therapeutics PTCT for the latter’s ...
Olema Oncology and Novartis partner for Phase 3 trial combining palazestrant with Kisqali for breast cancer treatment. Olema ...
Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “At ENA 2024, we presented three new, robust preclinical data sets. Palazestrant demonstrated combinability and ...
Short OLMA slightly under 9.33, target n/a, stop loss @ 9.36 Check the time stamp on this data. Updated AI-Generated Signals ...
Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be ...
A copy of the poster will be made available on the Publications page of Olema’s website in alignment with the Symposium’s embargo policy. Olema will hold a conference call to discuss these ...
EST Olema Oncology (OLMA) up 13% at $11.40 after entering supply pact with NovartisDon't Miss our Black Friday Offers:Unlock your ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback